Investigation of Corcept Therapeutics

Corcept Therapeutics Incorporated (CORT) Accused of Illicit Sales Practices

In 2012, Corcept Therapeutics Incorporated (CORT) launched its prescription medicine Korlym, which served as Corcept’s only revenue-generating product. Due to the limited population of potential Korlym users, Corcept’s officers and directors improperly paid doctors to prescribe Korlym for non-approved applications and disguised these bribes as speaking fees for its speakers bureau program. Corcept’s ruse was revealed on January 25, 2019, when Southern Investigative Reporting Foundation published a report alleging that Corcpet paid doctors to prescribe Korlym for off-label uses. In addition to this wrongdoing, on February 5, 2019, Blue Orca Capital published a report alleging that the specialty pharmacy Corcept switched to for processing Korlym orders was actually an undisclosed related party that Corcept was using to artificially boost sales and hide losses. As result of these revelations, Corcept’s public statements appeared to be materially false and misleading, damaging the Company’s credibility. As a result, Corcept has been named a defendant in a securities class action lawsuit, opening the Company up to future damages.

Corcept Therapeutics Incorporated (CORT) shareholders have options.

All representation is on a contingency fee basis.  Shareholders pay no fees or expenses.

Send us a message for more information.